---
title: "Analyst Reaffirms Buy on CMPS, Viewing Post-Data Pullback as Entry Opportunity Ahead of 1H27 Launch"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291970904.md"
description: "Wolfe Research analyst Rudy Li reaffirmed a Buy rating on CMPS, viewing the recent ~10% stock pullback as an entry opportunity ahead of the planned 1H27 launch. The bullish stance is supported by durable efficacy data for COMP006, improved responder rates, and a clean safety profile, which reinforce confidence in the upcoming NDA submission. Morgan Stanley also maintained a Buy rating with a $17 price target."
datetime: "2026-07-07T19:45:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291970904.md)
  - [en](https://longbridge.com/en/news/291970904.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291970904.md)
---

# Analyst Reaffirms Buy on CMPS, Viewing Post-Data Pullback as Entry Opportunity Ahead of 1H27 Launch

Wolfe Research analyst Rudy Li has maintained their bullish stance on CMPS stock, giving a Buy rating today.

### 4th of July Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Rudy Li has given his Buy rating due to a combination of factors tied to COMP006’s latest data and the company’s regulatory trajectory. He views the durable 26-week efficacy, improved responder and remission rates versus prior trials, and a clean safety profile as reinforcing confidence in the planned NDA submission and anticipated 1H27 commercial launch.

He also interprets the ~10% intraday share decline as a temporary “sell-the-news” reaction after a strong run toward 52-week highs, rather than a change in fundamentals. With management reaffirming timelines, demonstrating consistent durability across studies, and outlining a clear dosing framework, he sees the pullback as an attractive entry point and expects CMPS to regain momentum despite near-term volatility.

In another report released today, Morgan Stanley also maintained a Buy rating on the stock with a $17.00 price target.

### Related Stocks

- [CMPS.US](https://longbridge.com/en/quote/CMPS.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [Compass Pathways publishes investor presentation on COMP360 psilocybin program, FDA filing progress and launch plans](https://longbridge.com/en/news/294963906.md)
- [CMPS: Q2 2026 net loss widened to $253.8M; Phase 3 TRD milestones achieved; cash runway into 2028](https://longbridge.com/en/news/294951377.md)
- [Compass Pathways grants new-hire inducement equity awards at USD 11.25 per share](https://longbridge.com/en/news/295021252.md)
- [Evercore ISI Sticks to Their Buy Rating for Walt Disney (DIS)](https://longbridge.com/en/news/295118301.md)
- [BMO Capital Sticks to Its Buy Rating for MKS (MKSI)](https://longbridge.com/en/news/295118082.md)